Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe

Christopher H. Henshall, Dávid Dankó (), Leela Barham, Jaime Espín, Jorge Felix, Mary Harney, Peter Indra, Jorge Mestre-Ferrandiz, Gérard Pouvourville, Federico Spandonaro, Luka Vončina and Nils Wilking
Additional contact information
Dávid Dankó: Ideas & Solutions
Leela Barham: Leela Barham Economic Consulting Ltd
Jaime Espín: Andalusian School of Public Health
Jorge Felix: Exigo
Peter Indra: Amt für Gesundheit
Gérard Pouvourville: ESSEC Business School
Luka Vončina: University of Rijeka
Nils Wilking: Karolinska Institutet

Applied Health Economics and Health Policy, 2023, vol. 21, issue 4, No 2, 537-546

Abstract: Abstract Objectives Combinations of on-patent therapies (CTs) are increasingly common in oncology. They cause challenges for funding and affordability, and hence patient access, especially when constituent therapies are owned by different manufacturers. The aim of our study was to develop policy proposals for the assessment, pricing, and funding of CTs and identify which might be relevant in different European countries. Methods Following a review of available literature, seven hypothetical policy proposals were developed and subsequently assessed through 19 semi-structured interviews with health policy, pricing, technology assessment and legal experts in seven European countries to identify those most likely to gain traction. Results Experts saw a need for agreed approaches within a country to manage affordability and funding challenges for CTs. Changes to health technology assessment (HTA) and funding models were considered unlikely, but other policy proposals were seen as mostly useful, with country-specific adaptations. Bilateral discussions between manufacturers and payers were deemed important, and less challenging and protracted than arbitrated dialogue between manufacturers. Usage-specific pricing, possibly using weighted average prices, was considered a prerequisite for the financial management of CTs. Conclusions There is a growing need to ensure that CTs are affordable to health systems. It would appear that there is no one set of policies that is appropriate for all countries in Europe, so countries wishing to ensure that patients have (or continue to have) access to CTs of value to them must explore and implement the policies that are best suited to their general approach to funding health care and to the assessment and reimbursement of medicines.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-023-00795-8 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:21:y:2023:i:4:d:10.1007_s40258-023-00795-8

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-023-00795-8

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().